MedTrace Logo

ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen

NCT02943720 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 421

Last updated 2018-01-10

No results posted yet for this study

Summary

A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping Peptides Derived from Bet v 1, in Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis

Conditions

  • Allergic Rhinitis

Interventions

DRUG

AllerT

Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution

DRUG

placebo

placebo

Sponsors & Collaborators

  • Anergis

    lead INDUSTRY

Principal Investigators

  • Stephen Durham, MD · NHLI, Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-07-31
Completion
2017-10-31

Countries

  • Denmark
  • Finland
  • Germany
  • Lithuania
  • Norway
  • Poland
  • Slovakia
  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02943720 on ClinicalTrials.gov